

500 Chipeta Way Salt Lake City, UT 84108-1221 phone: 801-583-2787 | toll free: 800-242-2787 fax: 801-584-5249 | aruplab.com

Tax: 001-304-3249 | aruptab.com

THIS IS NOT A TEST REQUEST FORM. Please complete and submit with the test request form or electronic packing list.

GENOME SEQUENCING INTAKE FORM

Failure to provide required information for genome sequencing will result in suboptimal clinical reports and delays in testing.					
RE 1.		RED for Rapid Whole Genome Sequencing (3005935) or Whole Genome Sequencing (3016493): Date of Birth:			
2.		spected Clinical Diagnosis:			
		vide medical records detailing the patient's phenotype/relevant previous testing/family history or complete the ditional Clinical Information section found in this document.			
3.	Order Parental Control Samples Using Test Codes Below*. Submit comparator samples within 7 days of the proband's sample.				
	Rap	ntrols REQUIRED for Rapid Whole Genome Sequencing (3005935) oid Whole Genome Sequencing, Familial Control (3005928)—If no ACMG report desired oid Whole Genome Sequencing, Familial Control with Report (3005933)—If ACMG report desired			
		ntrols RECOMMENDED for Whole Genome Sequencing (3016493) ole Genome Sequencing, Familial Control (3016497)—Opt in below if ACMG report desired			
	a.	Maternal Last Name, First Name:			
		Date of birth: Clinically affected? No Yes:			
	b.	Paternal Last Name, First Name:			
		Date of birth: Clinically affected? □ No □ Yes:			

*Parental samples must arrive within 7 days of proband's order and are critical for optimal analysis. Nonparental controls are not acceptable. Due to the required clinical workflow, submitted nonparental controls may be sequenced, and if so, additional charges will apply.

4. Ordering Provider Attestation of Informed Consent (signature required below)

Test Purpose and Description

The purpose of whole genome sequencing is to identify the gene variant(s) causing a suspected genetic condition.

Testing requires drawing 2 mL of blood from which the DNA is extracted. DNA codes for genes. Most of the patient's genes will be sequenced. Thousands of DNA variants will be detected by sequencing. DNA variants may be disease causing or harmless; however, the effect of many DNA variants is currently unknown.

Ordering Considerations

Participation in whole genome sequencing is voluntary. Genetic counseling is recommended before and following this complex test.

The chance a cause for the patient's medical issue(s) can be determined using this test varies and is influenced by the specific clinical features present. Diagnostic rates are highest when biological parents' samples are included as comparators for whole genome sequencing. Parental

sequence data is used to identify de novo (new) changes in the patient's DNA, not found in either parent, that could explain the patient's disorder.

It is important that the familial biological relationships are correctly stated because undisclosed adoption or uncertain paternity will cause confusion and decrease the chance of identifying the causative disease variant.

Whole genome sequencing may identify genetic findings unrelated to the original reason for testing such as:

- Predict another family member has, is at risk for, or is a carrier of an unsuspected genetic condition.
- Reveal nonpaternity (the person stated to be the biological father is not, in fact, the biological father).
- Indicate the biological parents of the patient are close blood relatives (consanguineous).

Reporting of Results

Results are generally available in 1 week for rapid whole

ARUP-FORM-0014, Rev 3 | October 2024 | Page 1 of 5

GENOME SEQUENCING INTAKE FORM

genome sequencing and within 3 weeks for nonrapid whole genome sequencing. Variants that are known or suspected to be causative for the patient's medical issues are reported.

All variants identified in the patient that are related to the patient's primary disorder will be tested in familial controls. The status of all primary variants tested in controls will be indicated on the proband's report.

For nonrapid genome sequencing, candidate variants that are not known to be causative for the patient's medical issues, such as de novo variants (not inherited from either parent) or variants inherited from both parents in the same gene, may be reported even if the function of the gene is unknown.

Variants in genes unrelated to the patient's medical condition are not usually reported except for disease-causing secondary findings (see the Secondary Findings section below).

Because genetic knowledge is advancing at a rapid pace, reanalysis of whole genome sequencing data should be considered 12-18 months after testing is complete if a cause for the patient's condition was not determined. ARUP will perform reanalysis (ARUP test code 3005939) of whole genome data for a fee. If the report is amended, the ordering client will receive an updated report.

Limitations

Although genetic test results are usually accurate, several sources of error are possible, including clinical misdiagnosis of a condition, sample mislabeling or contamination, transfusion, bone marrow transplantation, maternal cell contamination of cord blood samples, or inaccurate information regarding biological relationships. If biological relationships are inaccurately reported, it could lead to an incorrect diagnosis or inconclusive result. ARUP will contact the referring provider if nonpaternity and/or consanguinity is detected but that information will not be included in the patient's report.

Often, whole genome sequencing is not able to identify the cause of a patient's medical issues. This does not exclude the possibility that the patient has a genetic condition. Some disease-causing variants are in genes with unknown function while others may not be identifiable using this test. Examples of variants not detectable with this test include large gene deletion/duplications, chromosome rearrangements, inversions, methylation abnormalities, and those causing repeat disorders. This test does not include sequencing of the mitochondrial genome.

Secondary Findings

The American College of Medical Genetics and Genomics (ACMG) recommends reporting disease-causing variants in specific genes that increase the risk for developing cancer, cardiovascular issues, metabolic disorders, problems with anesthesia, retinopathy, and other conditions where monitoring or early treatment may be available. Please refer to the latest version of the ACMG recommendations for reporting secondary findings in clinical whole genome sequencing for a list of genes and associated disorders

tested. Additional medically actionable variants in non-ACMG genes may be reported at ARUP's discretion.

If a patient has symptoms of a condition related to an ACMG recommended gene, separate testing should be ordered, as coverage of ACMG genes may be incomplete. Only variants in ACMG genes identified by routine whole genome sequencing are reported. Single disease-causing variants in recessive ACMG genes are not reported.

To receive secondary findings about the patient, the patient (or their legal guardian) would need to choose to receive this information by selecting the "opt-in" option on this form. Familial controls who desire a report of their own secondary findings can also opt-in to receive this information for a separate fee. Secondary findings will be reported for familial controls who elect to receive this information regardless of whether the finding was also identified in the patient. Parental inheritance of secondary findings identified in the patient will only be included in the patient's report if the positive parent also opts to receive secondary findings.

If a disease-causing genetic variant is identified, insurance rates, the ability to obtain disability and life insurance, and employability could be affected. The Genetic Information Nondiscrimination Act of 2008 extends some protections against genetic discrimination (genome.gov/10002328). All test results are released to the ordering healthcare provider and those parties entitled to them by federal, state, and local laws.

Access to Sequence Data/Data Sharing/Sample Storage

ARUP Laboratories will have access to the patient's sequence data from whole genome sequencing. Your healthcare provider and the hospital that submitted the test to ARUP can also request a copy of the sequence data.

Because ARUP is not a storage facility, most samples are discarded after testing is completed. Some samples may be stored indefinitely for test validation or education purposes after personal identifiers are removed. You may request disposal of your sample by calling ARUP Laboratories at 800-242-2787 ext. 3301.

In cooperation with the National Institutes of Health's effort to improve understanding of specific genetic variants, ARUP submits HIPAA-compliant, deidentified (cannot be traced back to the patient) genetic test results and health ARUP-FORM-0014, Rev 3 | October 2024 | Page 2 of 5

GENOME SEQUENCING INTAKE FORM

information to public databases. The confidentiality of each sample is maintained. If you prefer that your test result not be shared, call ARUP at 800-242-2787 ext. 3301.

Your deidentified information will not be disclosed to public databases after your request is received, but a separate request is required for each genetic test.

Additionally, patients have the opportunity to participate in patient registries and research. To learn more, visit aruplab.com/genetics

Ordering Healthcare Provider, Genetic Counselor: 1) I attest that I am the ordering health care provider or certified genetic counselor; 2) I have explained the purpose/benefits and limitations of the test to the patient or their legal guardian and all parental controls; 3) The patient/legal guardian and parental controls were offered copies of this consent document; 4) I have answered all their questions regarding the purpose of the test, the reporting of primary and secondary findings, the use and retention of samples, and data-sharing.

Ordering Provider/Genetic Counselor Prin	ted Name Signature	Date
Secondary findings identified WILL NOT b is checked. A fee applies for generating a		ent or controls UNLESS the corresponding bo ngs for control individuals.
$\hfill\Box$ Opt-in to report secondary findings for t	he PATIENT.	
$\hfill\Box$ Opt-in to report secondary findings for t	he MATERNAL CONTROL.	
$\hfill\Box$ Opt-in to report secondary findings for t	he PATERNAL CONTROL.	
For questions, cor	tact an ARUP genetic counselor at 8	300-242-2787 ext. 2141.
	ow. The ability to identify causative	vious testing/family history or complete the variant(s) for the patient's presentation is
Ordering Provider:	Provider's Pho	ne:
Practice Specialty:	Provider's Fax	
Genetic Counselor:	Counselor's Ph	one:
Ethnicity/Ancestry: □ African American/B	Black ☐ Asian ☐ Hispanic	☐ White ☐ Other:
Genes of Interest:		
Family History:		
PRE/PERINATAL ☐ 0000776 Congenital diaphragmatic	☐ 0001622 Prematurity—GA at birth	abnormality
hernia ☐ 0001627 Congenital heart defect	□ 0003026 Short long bones	☐ 0002539 Cortical dysplasia
☐ 00001627 Congenital heart defect ☐ 0000476 Cystic hygroma	☐ 0001518 Small for gestational age	e □ 0002282 Heterotopia □ 0001360 Holoprosencephaly
□ 0002084 Encephalocele	STRUCTURAL BRAIN ABNORMALITI	
☐ 0010945 Fetal pyelectasis	☐ 0002134 Abnormality of basal gar	
☐ 0007430 Generalized edema	\square 0002363 Abnormality of the brain	stem 0001339 Lissencephaly
☐ 0001789 Hydrops fetalis	☐ 0001273 Abnormality of corpus	□ 0002126 Polymicrogyria
☐ 0010880 Increased nuchal	callosum	□ 0002119 Ventriculomegaly
translucency	☐ 0002269 Abnormality of neuronal	
\square 0001511 Intrauterine growth restriction	migration	
□ 0002475 Myelomeningocele/spina bifida	 0007360 Aplasia/hypoplasia of th cerebellum 	e
☐ 0001562 Oligohydramnios	☐ 0012444 Brain atrophy	
☐ 0001539 Omphalocele	☐ 0007266 Cerebral dysmyelination	
□ 0001561 Polyhydramnios	☐ 0006808 Cerebral hypomyelinatio	n

ARUP-FORM-0014, Rev 3 | October 2024 | Page 3 of 5

GENOME SEQUENCING INTAKE FORM

NEUROLOGICAL	MUSCULOSKELETAL	EAR AND HEARING
☐ 0100022 Abnormality of movement	☐ 0002804 Arthrogryposis multiplex	☐ 0000377 Abnormal external ear
☐ 0001284 Areflexia	congenita	☐ 0000405 Conductive hearing
☐ 0001251 Ataxia	☐ 0003199 Decreased muscle mass	impairment
☐ 0002015 Dysphagia	☐ 0001371 Flexion contracture	☐ 0000410 Mixed hearing impairment
☐ 0001332 Dystonia	☐ 0001528 Hemihypertrophy	☐ 0000407 Sensorineural hearing
☐ 0100660 Dyskinesia	☐ 0001252 Hypotonia	impairment
☐ 0200134 Epileptic encephalopathy	□ 0001276 Hypertonia	
☐ 0001298 Encephalopathy	☐ 0001382 Joint hypermobility	CARDIAC
☐ 0001347 Hyperreflexia	☐ 0002808 Kyphosis	☐ 0001713 Abnormal cardiac ventricle
☐ 0004305 Involuntary movements	□ 0040064 Limb abnormality	☐ 0002616 Aortic root dilatation
☐ 0001250 Seizures	☐ 0001324 Muscle weakness	□ 0011675 Arrhythmia
☐ 0002121 Absence	☐ 0003198 Myopathy	☐ 0001631 Atrial septal defect
☐ 0002373 Febrile	☐ 0010442 Polydactyly	□ 0001647 Bicuspid aortic valve
☐ 0007359 Focal	☐ 0002757 Recurrent fractures	□ 0001638 Cardiomyopathy
☐ 0002123 Generalized myoclonic	☐ 0002650 Scoliosis	□ 0001680 Coarctation of aorta
☐ 0010818 Generalized tonic	☐ 0004322 Short stature	☐ 0001642 Pulmonary stenosis
☐ 0011169 Generalized clonic	☐ 0002652 Skeletal dysplasia	☐ 0001636 Tetralogy of Fallot
☐ 0012469 Infantile	☐ 0001257 Spasticity	□ 0001629 Ventricular septal defect
□ 0002069 Tonic-clonic	☐ 0001159 Syndactyly	
	☐ 0001762 Talipes equinovarus	
METABOLIC	☐ 0000098 Tall stature	GASTROINTESTINAL
☐ 0040081 Abnormal CK	☐ 0000925 Vertebral column abnormality	□ 0002251 Aganglionic megacolon
☐ 0001941 Acidosis		□ 0002910 Elevated hepatic transaminase
☐ 0003234 Decreased plasma carnitine	CRANIOFACIAL	□ 0001508 Failure to thrive
☐ 0003348 Hyperalaninemia	□ 0000271 Abnormal facies	□ 0001543 Gastroschisis
☐ 0001943 Hypoglycemia	□ 0000306 Abnormality of the nose	□ 0001399 Hepatic failure
☐ 0001987 Hyperammonemia	□ 0000290 Abnormality of the forehead	□ 0002240 Hepatomegaly
☐ 0002490 Increased CSF lactate	□ 0000175 Cleft palate	☐ 0002021 Pyloric stenosis
☐ 0003542 Increased serum pyruvate	□ 0410030 Cleft lip	□ 0001744 Splenomegaly
☐ 0001946 Ketosis	□ 0001363 Craniosynostosis	☐ 0002013 Vomiting
☐ 0003128 Lactic acidosis	□ 0000286 Epicanthus	
☐ 0001942 Metabolic acidosis	□ 0000316 Hypertelorism	GENITOURINARY
☐ 0001992 Organic aciduria	□ 0000601 Hypotelorism	☐ 0000812 Abnormal internal genitalia
☐ Abnormal newborn screen	□ 0000256 Macrocephaly	□ 0000062 Ambiguous genitalia
	□ 0000252 Microcephaly	☐ 0000028 Cryptorchidism
		☐ 0000085 Horseshoe kidney
DEVELOPMENTAL/BEHAVIORAL		☐ 0000126 Hydronephrosis
□ 0007018 Attention deficit hyperactivity	EYE AND VISION	☐ 0000047 Hypospadias
disorder	□ 0000526 Aniridia	\square 0008738 Partially duplicated kidney
☐ 0000729 Autistic spectrum disorder	☐ 0000528 Anophthalmia	☐ 0000113 Polycystic kidney dysplasia
□ 0000750 Delayed speech and language	☐ 0000618 Blindness	☐ 0000107 Renal cyst
development	□ 0000589 Coloboma	☐ 0000104 Renal agenesis
☐ 0002376 Developmental regression	□ 0000519 Congenital cataract	☐ 0000089 Renal hypoplasia
□ 0001263 Global developmental delay	☐ 0000568 Microphthalmia	☐ 0000069 Ureter abnormality
☐ 0001249 Intellectual disability	☐ 0000639 Nystagmus	☐ 0000795 Urethra abnormality
☐ 0002187 Profound	□ 0000648 Optic atrophy	
☐ 0010864 Severe	□ 0000508 Ptosis	SKIN AND HAIR
☐ 0002342 Moderate	□ 0009919 Retinoblastoma	□ 0008066 Blistering of skin
□ 0001256 Mild	□ 0000486 Strabismus	□ 0000957 Café-au-lait spot
☐ 0001270 Motor delay	□ 0000505 Visual impairment	□ 0005306 Capillary hemangioma
		□ 0001595 Hair abnormality
		□ 0000974 Hyperextensible skin
		□ 0000953 Hyperpigmentation of skin
		□ 0000998 Hypertrichosis

ARUP-FORM-0014, Rev 3 | October 2024 | Page 4 of 5

GENOME SEQUENCING INTAKE FORM ENDOCRINE OTHER ☐ 0001010 Hypopigmentation of skin ☐ 0000834 Abnormality of adrenal glands □ 0008066 Ichthyosis ☐ 0008226 Androgen insufficiency □ 0001597 Nail abnormality ☐ 0001581 Recurrent skin infections ☐ 0008258 Congenital adrenal hyperplasia ☐ 0000819 Diabetes mellitus HEMATOLOGY AND IMMUNOLOGY ☐ 0000873 Diabetes insipidus ☐ 0001928 Abnormality of coagulation ☐ 0001738 Exocrine pancreatic ☐ 0004432 Agammaglobulinemia insufficiency ☐ 0001903 Anemia ☐ 0000821 Hypothyroidism ☐ 0031020 Bone marrow hypercellularity ☐ 0000829 Hypoparathyroidism ☐ 0001878 Hemolytic anemia ☐ 0002721 Immunodeficiency CANCER □ 0001888 Lymphopenia ☐ Type of cancer ☐ 0001875 Neutropenia ☐ Age of diagnosis____ ☐ 0001876 Pancytopenia ☐ Family history of cancer and ☐ 0002719 Recurrent infections affected relatives ☐ 0004430 Severe combined immunodeficiency ☐ 0001873 Thrombocytopenia PREVIOUS TESTING (provide copy of abnormal results) Echocardiogram: ☐ Not performed □ Normal ☐ Abnormal EEG: ☐ Not performed □ Normal ☐ Abnormal EMG/NCV: □ Not performed □ Normal □ Abnormal _ Gene testing: □ Normal □ Abnormal Gene testing: □ Normal □ Abnormal □ Abnormal Karyotype: □ Not performed □ Normal Prenatal genomic microarray: ☐ Not performed □ Normal □ Abnormal Postnatal genomic microarray: □ Not performed □ Normal □ Abnormal _ MRI (brain): ☐ Not performed □ Normal □ Abnormal _ MRI (other): ☐ Not performed □ Normal □ Abnormal _ CT (brain): ☐ Not performed ☐ Normal ☐ Abnormal CT (other): ☐ Not performed □ Normal □ Abnormal _ Muscle biopsy: ☐ Not performed □ Normal □ Abnormal _ Ultrasound ☐ Not performed □ Normal □ Abnormal ☐ Not performed □ Normal X-ray: □ Abnormal _ □ Normal Other test: ☐ Abnormal Other test: □ Normal ☐ Abnormal □ Normal Other test: ☐ Abnormal

ARUP-FORM-0014, Rev 3 | October 2024 | Page 5 of 5